NEW YORK (GenomeWeb News) – Investment firm Credit Suisse has initiated coverage of six companies operating in the life science tools and molecular diagnostics space.
On Wednesday analyst Vamil Divan initiated coverage on Illumina, Life Technologies, Thermo Fisher Scientific, Cepheid, Qiagen, and Waters.
Illumina was given a Neutral rating and a $30 target price on its stock. Divan estimated 2011 revenues at $1.05 billion, and 2012 revenues at $1.07 billion. He provided an EPS estimate for 2011 at $1.20 and for 2012 at $1.29.